Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $763.36 million. The enterprise value is $1.03 billion.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 83.15 million shares outstanding. The number of shares has increased by 6.77% in one year.
| Current Share Class | 67.37M |
| Shares Outstanding | 83.15M |
| Shares Change (YoY) | +6.77% |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 37.79% |
| Float | 33.35M |
Valuation Ratios
The trailing PE ratio is 26.79 and the forward PE ratio is 11.75. Bioventus's PEG ratio is 1.07.
| PE Ratio | 26.79 |
| Forward PE | 11.75 |
| PS Ratio | 1.35 |
| Forward PS | 1.26 |
| PB Ratio | 3.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 10.66 |
| P/OCF Ratio | 10.29 |
| PEG Ratio | 1.07 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 13.25, with an EV/FCF ratio of 14.26.
| EV / Earnings | 45.24 |
| EV / Sales | 1.81 |
| EV / EBITDA | 13.25 |
| EV / EBIT | 18.25 |
| EV / FCF | 14.26 |
Financial Position
The company has a current ratio of 1.70, with a Debt / Equity ratio of 1.36.
| Current Ratio | 1.70 |
| Quick Ratio | 1.12 |
| Debt / Equity | 1.36 |
| Debt / EBITDA | 3.74 |
| Debt / FCF | 4.32 |
| Interest Coverage | 2.13 |
Financial Efficiency
Return on equity (ROE) is 13.17% and return on invested capital (ROIC) is 11.33%.
| Return on Equity (ROE) | 13.17% |
| Return on Assets (ROA) | 4.99% |
| Return on Invested Capital (ROIC) | 11.33% |
| Return on Capital Employed (ROCE) | 10.77% |
| Weighted Average Cost of Capital (WACC) | 7.67% |
| Revenue Per Employee | $610,846 |
| Profits Per Employee | $24,443 |
| Employee Count | 930 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 2.06 |
Taxes
| Income Tax | -1.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.97% in the last 52 weeks. The beta is 0.69, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +11.97% |
| 50-Day Moving Average | 8.64 |
| 200-Day Moving Average | 7.51 |
| Relative Strength Index (RSI) | 58.26 |
| Average Volume (20 Days) | 442,190 |
Short Selling Information
The latest short interest is 1.42 million, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 1.42M |
| Short Previous Month | 1.44M |
| Short % of Shares Out | 1.71% |
| Short % of Float | 4.27% |
| Short Ratio (days to cover) | 4.12 |
Income Statement
In the last 12 months, Bioventus had revenue of $568.09 million and earned $22.73 million in profits. Earnings per share was $0.33.
| Revenue | 568.09M |
| Gross Profit | 388.16M |
| Operating Income | 56.34M |
| Pretax Income | 25.71M |
| Net Income | 22.73M |
| EBITDA | 77.64M |
| EBIT | 56.34M |
| Earnings Per Share (EPS) | $0.33 |
Full Income StatementBalance Sheet
The company has $51.24 million in cash and $311.35 million in debt, with a net cash position of -$260.11 million or -$3.13 per share.
| Cash & Cash Equivalents | 51.24M |
| Total Debt | 311.35M |
| Net Cash | -260.11M |
| Net Cash Per Share | -$3.13 |
| Equity (Book Value) | 228.45M |
| Book Value Per Share | 2.74 |
| Working Capital | 112.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $74.67 million and capital expenditures -$2.56 million, giving a free cash flow of $72.11 million.
| Operating Cash Flow | 74.67M |
| Capital Expenditures | -2.56M |
| Depreciation & Amortization | 21.30M |
| Net Borrowing | 22.86M |
| Free Cash Flow | 72.11M |
| FCF Per Share | $0.87 |
Full Cash Flow StatementMargins
Gross margin is 68.33%, with operating and profit margins of 9.92% and 4.00%.
| Gross Margin | 68.33% |
| Operating Margin | 9.92% |
| Pretax Margin | 4.53% |
| Profit Margin | 4.00% |
| EBITDA Margin | 13.67% |
| EBIT Margin | 9.92% |
| FCF Margin | 12.69% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.77% |
| Shareholder Yield | -6.77% |
| Earnings Yield | 2.96% |
| FCF Yield | 9.39% |
Analyst Forecast
The average price target for Bioventus is $14.00, which is 52.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.00 |
| Price Target Difference | 52.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 6.90% |
| EPS Growth Forecast (5Y) | 29.72% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.29 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.29 |
| Piotroski F-Score | 8 |
